Abstract:Toxoplasma gondii is an intracellular protozoan parasite that infects all nucleated cells except the red blood cells. Currently, nucleic acid vaccines are being widely investigated in Toxoplasma gondii control, and several nucleic acid vaccine candidate antigens have shown good protection in various studies. The aim of this study was to construct a nucleic acid vaccine with Toxoplasma gondii SRS29C as the target gene. We explored the nucleic acid vaccine with Toxoplasma surface protein SRS29C and the combined gene of SRS29C and SAG1 and evaluated its immunoprotective effect against Toxoplasma gondii. To amplify the gene fragment and clone it to the expression vector, the recombinant plasmid pEGFP-SRS29C was constructed by PCR. Eukaryotic cells were transfected with the plasmid, and the expression of the target protein was assessed using the Western blot method. The level of serum IgG was determined via ELISA, and the splenic lymphocyte proliferation ability was detected using the CCK-8 method. The percentages of CD4+ and CD8+ T cells were measured by flow cytometry. Mice were immunised three times with single-gene nucleic acid vaccine and combination vaccine. Splenic lymphocytokine expression was determined using ELISA kits. The mice's survival time was monitored and recorded during an in vivo insect assault experiment, and the vaccine's protective power was assessed. The outcomes showed that PCR-amplification of an SRS29C gene fragment was successful. The 4,733-bp vector fragment and the 1,119-bp target segment were both recognised by double digestion. Additionally, after transfection of the recombinant plasmid pEGFP-SRS29C, Western blot examination of the extracted protein revealed the presence of a target protein strip at 66 kDa. The test results demonstrated that the IgG content in the serum of the pEGFP-SRS29C group and the co-immunization group was significantly higher than that of the PBS group and the empty vector group. The IgG potency induced by the co-immunization group was higher than that of the pEGFP-SRS29C group and the pEGFP-SAG1 group, the number of splenic lymphocyte proliferation number was higher than that of the PBS group and the empty vector group. The CD4+/CD8+ T ratio was higher than that of the PBS group and the empty vector group. The expression of IFN-γ and TNF-α in the splenocytes of the pEGFP-SRS29C group and the combined immunisation group was significantly higher following antigen stimulation. In the worm attack experiments, mice in the PBS and empty vector groups perished within 9 days of the worm attack, whereas mice in the pEGFP-SRS29C group survived for 18 days, mice in the pEGFP-SAG1 group survived for 21 days, and mice in the co-immunization group survived for 24 days. This demonstrates that the constructed Toxoplasma gondii nucleic acid vaccine pEGFP-SRS29C and the combined gene vaccine can induce mice to develop certain humoral and cellular immune responses, and enhance their ability to resist Toxoplasma gondii infection.

Construction of Co-expressing Plasmids of AgB from Taenia Solium with Porcine CD58 or IFN-γ Gene and Expression in BHK-21 Cells

Construction of Gene Vaccine Vector Carrying TSOL18 Gene of Taenia Solium Oncosphere and Its Immunogenicity

Combining Expression and Protective Efficacy of 45W-4BX and 18kd from Different Stages of Taenia Solium

Expression of the Recombinant DNA Vaccine Pcdna 3.1-TSO45-4B Against Cysticercosis Cellulosae and Cell Immunity Response in Mice

Highly Efficacious Expression and Immune Efficacy of Recombinant 45W-4BX and TSOL18 from Taenia Solium Oncosphere

Cloning of Cysticercus Cellulosae AgB Gene by Using Splicing Overlap Extension PCR Method and Expression in BHK Cells.

Effective Production and Purification of the Glycosylated TSOL18 Antigen, Which is Protective Against Pig Cysticercosis

Construction of Eukaryotic Expression Plasmids with Cryptosporidium Mouse Genotype CP15 Gene and Their Expression in Hela Cells

Construction and identification of recombinant Mycobacterium smegmatis vaccine expressing Cysticercus cellulosae cC1 antigen]

Analysis of immune response in BALB/c mice immunized with recombinant plasmids pMZ-X3-Ts14–3–3.3 and pMZ-X3-sp-Ts14–3–3.3 of Taenia solium

Optimized codon usage enhances the expression and immunogenicity of DNA vaccine encoding Taenia solium oncosphere TSOL18 gene.

Studies on the Development of DNA Vaccine Against Cysticercus Cellulosae Infection and Its Efficacy.

[Cloning and efficient prokaryotic expression of soluble stage-specific antigen cC1 from Cysticercus cellulosae]

Construction of Eukaryotic Vector Expressing Taenia solium dUTPase and Its Expression in BHK Cell Line

Prokaryotic Expression and Purification of Recombinant TS-CC18 Antigen from Cysticercus Cellulosae and Identifica-tion of Its Antigeuicity

[Combined Expression of TSO45W-4BX from Taenia Solium and Porcine CD58 in Escherichia Coli].

Preparation of Rabbit Sera of Anti-Taenia Solium Onchosphere and in Vivo Expression of Recombinant Plasmid Pcdna3.1/tso45-4B in Skeletal Muscle of Vaccinated Mice

Construction of Toxoplasma gondii SRS29C nucleic acid vaccine and comparative immunoprotective study of an SRS29C and SAG1 combination

Construction,expression and gene immunization of eukaryotic expression vector containing cfp10 of Mycobacterium tuberculosis

Adjuvant Effects of Recombinant Plasmids of Porcine IL-4 and IFN-γ to Cysticercosis Cellulosae Vaccines in Mice and Pigs

Construction of recombinant SAG22 Bacillus subtilis and its effect on immune protection of coccidia